Synaptogenix, Inc.
NASDAQ: SNPX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alan J. Tuchman MBA(FAAN)
- Employees
- 4
- Headquarters
- New York City, United States
- IPO year
- 2020
- Market cap
- $10.9M
- Website
- https://www.synaptogen.com
Loading SNPX…
Loading profile data…Frequently asked questions about SNPX
What does Synaptogenix, Inc. (SNPX) do?
Synaptogenix, Inc. operates as a biopharmaceutical entity, actively advancing multiple product candidates through both preclinical and clinical development stages. The company's primary focus involves establishing a therapeutic platform centered on Bryostatin-1, a key drug candidate, primarily for the treatment of Alzheimer's disease. Additional...
Where does SNPX trade?
Synaptogenix, Inc. (SNPX) trades on the NASDAQ Capital Market.
What sector is SNPX in?
Synaptogenix, Inc. (SNPX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Synaptogenix, Inc.?
Alan J. Tuchman MBA(FAAN) is the chief executive officer of Synaptogenix, Inc. (SNPX).
Where is Synaptogenix, Inc. headquartered?
Synaptogenix, Inc. is headquartered in United States.
Does SNPX pay a dividend?
Synaptogenix, Inc. (SNPX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SNPX go public?
Synaptogenix, Inc. (SNPX) completed its initial public offering in 2020.